A+ A  A- Skip to main

SENSEX 76059.77 (-0.43)| 

Nifty 50 23767.45 (-0.43)| 

Nifty Bank 56693.5 (0.18) | 

Nifty IT 28767.95 (0.82) | 

Nifty Midcap 100 61622.35 (-0.10)| 

Nifty Next 50 71766 (-0.10)| 

Nifty Pharma 25548.15 (-0.41)| 

Nifty Smallcap 100 18874.95 (-0.32)| 

Indian Market
Nifty 50 48,450.45 +541.45 | 0.85%
Nifty 100 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Global Market
Nifty 50 48,450.45 +541.45 | 0.85%
Nifty 100 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
News
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
Ipca teams with BioSimilar Sciences PR LLC
(24 Sep 2025)

Ipca Laboratories and BioSimilar Sciences PR LLC (BSS) today announced a definitive Technology Transfer and Joint Development Agreement that will shift late-stage development, clinical manufacture, and commercial supply of a next generation anti-cancer / anti-inflammatory monoclonal antibody biosimilar being developed by Ipca to BioSimilar Sciences PR LLC (BSS) 200,000 square feet sterile campus in Aguadilla, Puerto Rico.